Author: admin

Boston Scientific Announces the approval and marketing in Europe of the coronary stent for cromo platino OMEGA (TM).

|

Boston Scientific Announces the approval and marketing in Europe of the stent coronary cromo-platino OMEGA Tm.

-the metal stent of third generation offers a better performance in the treatment of patients with coronary artery disease

Natick, Massachusetts, March of 2011. Boston Scientific Corporation (NYSE: BS) announced on Monday the acquisition of the CE marking to the coronary stent for cromo-platino OMEGA (TM), which is for the company technology of third generation of coronary stents. OMEGA incorporates a unique alloy of cromo-platino (PtCr), designed specifically for coronary stents, and aims to provide the interventionist cardiologists metallic stent for best performance for the treatment of patients with atherosclerosis. The company will start marketing OMEGA immediately in the European Union and other countries for the application of the CE marking.

“In my experience, cromo-platino alloy and OMEGA stent design offer an excellent seaworthiness, visibility and flexibility, allowing at the same time improve the radial force and the recoil”, says Dr. Antonio Colombo, Director of the laboratory of cardiac catheterization at Columbus Hospital and Hospital San Raffaele in MilanItaly. “OMEGA and cromo-platino alloy offer significant improvements in performance, without the disadvantages associated with the alloys normally used in stents.

“OMEGA is part of the family of stents Boston Scientific cromo-platino the PROMUS Element â„¢ everolimus-eluting stent and TAXUS r Element Tm paclitaxel-eluting stent. The three have the novel alloy of PtCr and an innovative design, which combine to offer a greater radial strength and flexibility, while minimizing the recoil of the stent. The highest density of alloy provides better visibility, allowing at the same time reducing the profile of the legs of the stent compared to previous generations. The release also has been optimized, consists of a double-layer ball designed to improve access to the most difficult injury.

“Cromo-platino PROMUS Element and Element TAXUS stent have received a positive response from physicians since its launch in countries for the application of the CE marking, and we now have the pleasure of presenting a metallic coronary stent, based on the same platform of PtCr,” says Mike Phalen, Executive Vice President and President International of Boston Scientific. “OMEGA is the latest example of our commitment” innovation continued in the area of coronary stents. “”We are convinced that our cromo-platino stent technology will strengthen our leadership in the market of the stent coronary.”

“Positive clinical data from our studies with stents of ≪ PtCr (Element)
confirm the beneficial effects of our new platform of cromo-platino “, commented Dr. Keith D. Dawkins, Vice President and Director Médico of the Group of Cardiology, rhythm and Vascular of Boston Scientific.””Complete OMEGA family of PtCr stents, offering the Interventional cardiologist the possibility of treating patient with everolimus and paclitaxel stent metallic.”

OMEGA is available in 48 sizes with diameters of 2.25 mm 4,50 mm and lengths of 8 mm to 32 mm. Boston Scientific hosts and makes available to physicians and patients the most comprehensive range of coronary stents, the wider range of measures and the only platform with two options of drug. The company obtained the CE marking for the PROMUS Element everolimus-eluting stent in October 2009 and the eluting stent to paclitaxel TAXUS r Element Tm in May 2010.

The adoption of the CE marking for PROMUS Element Plus is scheduled for the second half of 2011.

About Boston Scientific

Boston Scientific is a company dedicated to the development, manufacture and marketing of medical devices around the world, and its products are used in a wide range of medical specialties interventionists.

warning on statements of a forward-looking nature

this press release contains statements of a forward-looking nature as described in Section 21E of the securities market law)Securities Exchange Act) 1934 American. These statements of a forward-looking nature can be identified by the use of words such as “anticipate”, “expect”, “project”, “believe”, “plan”, “plan”, “estimate” and other similar terms. These statements of a forward-looking nature are based on our beliefs, assumptions and estimates, derived from the data that was available at the time of issuing such statements and are not intended to be the guarantee of any event or performance level futures. Other statements of a forward-looking nature include those related to clinical trials, scientific activities, performance products, competitive bids, and growth investments. If the assumptions on which we base were to be incorrect, or if they materialize certain risks or doubts, the results could be substantially different expectations and forecasts expressed or implied by our forward-looking statements. In some cases, these factors have affected and could affect (alongside other factors) our ability to establish a business strategy, and may cause actual results to differ significantly from those referred to in the statements expressed in this press release. He is therefore warns the reader that it does not deposit an excessive confidence in any of our statements of a forward-looking nature.

Among others, factors that could cause such differences include: the economic, competitive, conditions of repayment and future regulation; the emergence of new products; demographic trends; the intellectual property; the litigation; financial market conditions; and business decisions that take our company and competing companies. All these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a list and a description detailed of these and other risks and important questions that could affect our future operations, see item 1A, part I, risk factors for our latest annual report on form 10-K, submitted to the Commission of stock marketIt may be updated at point 1A, part II, risk factors in the quarterly reports on form 10-Q we have presented or present later.

We disclaim any intention or obligation to update or modify publicly any affirmation of a prospective basis to reflect changes in our expectations or in events, conditions or circumstances in which those expectations could be based, or that might affect the likelihood that actual results may differ from those mentioned in the statements of a forward-looking nature. This warning statement is applicable to all prospective character statements contained in this document.

Read More

The Cook Medical drug eluting peripheral stent proves a few solid results at 24 months in comparison with the data of one year.

|

Cook Medical drug-eluting peripheral stent demonstrates solid results at 24 months in comparison with the data of a year.

A randomized, multicenter study has evaluated the releasing device of drugs Zilver PTX, with CE mark, for the treatment of the Peripheral Arterial Disease in the femoral artery superficial.

Leipzig, Germany, February, 2011--the eluting stent drugs Zilver PTX of Cook Medical, available for the community health of the European Union, showed a consistent permeability initial two years of its implementation, in comparison with the first year, according to a random study presented at Leipzig Interventional Course. Data collected from 479 patients in a randomized trial showed that patients with this self-expanding nitinol stent and coated drug paclitaxel, presented an initial permeability of 83.1% at 12 months. When it became the test at 24 months, the rate of permeability in a poll 278 patients was 74.8 per cent. Data from the study showed that patients treated with Zilver PTX reached a survival rate of 86.6% in 24 months.

PAD, also known by the “ hardening ” the arteries or atherosclerosis occurs when deposits of fat and inflammation reduce blood flow in the lower extremities. The so-called Peripheral Arterial Disease suffer from it 27 million people in Europe and North America ¹. The test with the PTX Zilver trial confirms the safety and efficacy of the device of Cook for the treatment of severe complications in the superficial femoral artery.

The randomized study, the largest its kind that takes place at the global level, is complemented by a universe of 787 patients in several countries, which includes diabetics and patients with symptoms and complex injuries.

_
¹ Belch JJ, Topol EJ, Agnelli G, et to the. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163 (8): 884-892.

“ This trial has been rigorously designed to provide a real prospect the current treatment of Peripheral Arterial Disease worldwide, and we are very satisfied of the results has provided us with ”, said Rob Lyles, Global Chief and Vice President of the Division Peripheral Intervention, of Cook Medical. “ in Cook are committed in developing technologies to make progress in medicine, minimally invasive to the largest possible population ”.

About LINC

Leipzig Interventional Course is a course in international and exhaustive live designed to encourage collaboration among colleagues in different specialties and promote the understanding and development of therapies Endovascular that can be incorporated into the practical clinical daily.

About Cook Medical

founded in 1963, Cook Medical was the first company to implement much of the medical device to today used around the world in order to perform minimally invasive medical procedures in the human body. Currently, the company manufactures and markets medical devices, drugs and biological products employed in improving the safety and clinical outcomes of patients. Since its inception, Cook has operated as a private family-run company.

Read More

RapiScan r (regadenoson) is the first selective receptor adenosine A2A agonist.

|

RapiScan r (regadenoson) is the first selective A2A agonist receptor of adenosine.

-Rapiscan r (regadenoson) is the first selective agonist receptor adenosine A2A to receive the license of the Commission on the EU to help diagnosis CAD

London, February 2011. Rapidscan Pharma Solutions (RPS) us Ltd has announced that it has received last Friday permission marketing for Rapiscan r (regadenoson) – a coronary vasodilator selective for use as a pharmacologic stress agent in diagnosis of coronary artery disease (CAD) – the most common single cause of death and disability in Europe [1]. RapiScan is administered as a bolus injection not based on the weight and is the first and only receptor agonist selective adenosine A2A on having license for its use in this indication.

Diagnosis of CAD used the image of perfusion of myocardial infarction (MPI) to identify areas of poor in heart blood flow while resting or practice exercise. Often ask patients to do exercises in a wheel of walking or biking, but almost half of the patients are not able to exercise properly. RapiScan stimulates the effects of the exercise by increasing temporarily the flow of blood through the arteries of the heart, providing an option for these patients. Unlike the older agents, Rapiscan needs no adjustment of the dose for the variation in body weight [2] and its method of bolus dosage is fast (only 10 seconds), reducing the need for a pump infusion and its implementation to point.

The founder, CEO and Managing Director of Rapidscan Pharma Solutions, Dr. Brent Blackburn, said: “I am very excited for Rapiscan Europe.” RapiScan is designed to address specifically the needs of patients and health professionals to perform tests MPI. “It is easier to use and is tolerated better than older agents.”

Each year, more than 4 million Europeans die from diseases of the heart and blood vessels [1], accounting for about half of the total mortality in Europe [1]. Accurate diagnosis is vital in identifying patients who are suitable for intensive medical intervention with more than 1.5 million Europeans undergo MPI annual testing.

Regadenoson was released in United States in the year 2008 after performing clinical trials in more than 2,000 patients with known CAD or suspect [3,4]. Currently, regadenoson is used more broadly as agents against pharmacological stress in United States, and more than 3 million patients have received you.

More about regadenoson

Regadenoson is an agonist receptor selective A2A adenosine approved as an agent of pharmacologic stress in radionuclide MPI in patients unable to undergo adequate exercise testing. Regadenoson was discovered and developed by CV Therapeutics and received FDA approval in April 2008 and also received the US License Commission by the European medicines Agecia in September 2010.

About Rapidscan Pharma Solutions (RPS)

Rapidscan Pharma Solutions Inc, headquartered in United States, was created in the year 2010 through its general director and Chief Executive Officer, Dr. Brent Blackburn. In September 2010 RPS Inc. licensed the rights for the development, manufacture and marketing of regadenoson from Gilead Sciences Inc. for Europe, Japan, Australia, New Zealand and Israel. Its European subsidiary, RPS us Ltd, is responsible for the marketing of regadenoson in Europe. Dr. Blackburn has previously worked with CV Therapeutics and was a leading member of the team that discovered and developed regadenoson United States and Europe.

–
Referencia:

[1] Scholte op Reimer WJM, Gitt AK, Boersma E, Simoons ML (eds.). Cardiovascular Diseases in Europe. Euro Heart Survey – 2006. Sophia Antipolis; European Society of Cardiology; 2006

[2]. RapiScan Summary of Product Characteristics. Gilead Sciences; September 2010.

[3]. Cerqueira MD, Nguyen P, Staehr P et to, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008; 1: 307-316

[4]. Iskandrian AE, Bateman TM, Belardinelli L, et to the. Adenosine versus Rapiscan comparative evaluation in many imaging myocardial: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14: 645-658

Read More

More than half of all men between 40 and 70 years suffers from erectile dysfunction.

|

More than half of all men between 40 and 70 years suffers from dysfunction erectile.

10th workshop theoretical Sorecar (rehabilitation Cardiorrespiratoria Spanish society). Update on rehabilitation cardiaca.

-erectile dysfunction is defined as the inability to achieve and/or maintain one erection sufficient for satisfactory sexual intercourse

-prevalence estimated by the year 2025 is to affect 300 million men

– in the patients with coronary arterial erectile dysfunction prevalence ranges from 47-75%. Erectile dysfunction is more severe the more severe is the involvement of the coronary arterial tree

-erectile dysfunction and coronary artery disease share risk factors and mechanisms of production (vascular dysfunction)

– there is scientific evidence that erectile dysfunction may precede the onset of coronary symptoms in 5 years, which could be used as ‘ therapeutic window ’

-the final step of treatment is represented by the prosthesis of penis

Málaga, 2011-February one of every two males between 40 and 70 years suffers from erectile dysfunctionincluding all grades that this failure encompasses (mild, moderate and severe) and increasing its prevalence with age. This problem, which is defined as the inability to achieve and/or maintain one erection sufficient for satisfactory sexual intercourse, is common in men from around the world. In fact, the prevalence estimate for the year 2025 is to affect 300 million men.

Dr. Antonio Quiñonero, urologist of the unity of cardiac rehabilitation of Hospital Universitario Virgen of the victory of Malaga, spoke on erectile dysfunction in the framework of the theoretical and practical course 10th SORECAR (society Spanish of rehabilitation Cardio-respiratory) – branch of the SERMEF (Spanish society of rehabilitation and physical medicine) – Actualizaciis in cardiac rehabilitation, which took place on 27 and January 28 in the Hospital of Virgen de la Victoria, in Málaga.

“ In the patients with coronary arterial erectile dysfunction prevalence ranges between 47-75%. Erectile dysfunction is more severe the more severe is the involvement of the coronary arterial tree ”, the expert explained. “ In this sense ”, has been added, “ erectile dysfunction and coronary artery disease share risk factors and mechanisms of production, such as Endothelial dysfunction ”, explains the lecturer.

“ In addition, and perhaps most important is the growing scientific evidence that erectile dysfunction may precede the onset of coronary symptoms even in five years, which could be used as ‘ therapeutic window ’ ”.

Two types of patients

On the other hand, and patients, Dr. Quiñonero has pointed out that “ clinically we can find two different frames. On the one hand they are patients with erectile dysfunction under 60 years of age and without coronary symptoms who have a high risk of coronary heart disease in the next 5-10 years. These patients should be evaluated medically and stratified according to coronary risk medically to act on associated diseases (hypertension, diabetes, metabolic syndrome) and change the lifestyle (sedentary lifestyle, tobacco) ”.

On the other hand, “ are patients who have already had a coronary table (myocardial infarction, bypass coronary etc.). These patients should be integrated systematically into programs of cardiac rehabilitation (cardiac rehabilitation units) after his recovery from the acute process. The patient after being discharged is unknown as a deal with his new situation from many points of view: level exercise that can perform, nutrition, control of risk factors, stress-management techniques, the sexual problems (erectile dysfunction) and psychological repercussions. In these programs patients are instructed in all these areas, it is vitally important to optimize their clinical progression and improve their quality of life psycho-social, labour and sexual.

With regard to the processing, according to the expert, the erectile dysfunction currently has treatment, which starts in first-line oral drug (inhibitors of Phosphodiesterase-5) in those patients who are not contraindicated. In the case where patients may not take these drugs, “ can be treated in second-line drugs vasoactive injected directly into the penis. The final step of treatment is represented by the prosthesis of penis ”.

Read More

ISCT launches Group of commercial development of cell therapy for peripheral vascular disease.

|

ISCT launches Group of commercial development of the cell for vascular disease therapy peripheral.

-International Society for Cellular Therapy (ISCT) launches the Group’s commercial development of the inaugural cell therapy for peripheral vascular disease

Vancouver, January of 2011. To maintain its commitment to connect industry, regulatory experts, medical societies and translational centres to advance emerging cell therapies, ISCT announces its first group of business development for cell therapies for peripheral vascular disease (PVD).

The PVD is a disease in which the arteries that carry blood to the extremities become narrow or coagulan. In a population of primary care defined by age and common risk factors the prevalence of PVD is about one in three (1). Limb ischemia (CLI) critical is a very serious condition of developing countries in which patients suffering from acute pain and ulcers on the skin which can lead to amputation of the limb. The CLI has a mortality rate of 15-30% at 5 years.(2)

To treat the debilitating disease, ISCT has created a progressive Forum to bring together a panel of experts and facilitate open and in-depth discussion of whether Cellular therapy can meet the needs not covered these patients and how. The focus group will take place in New York, United States. UU., in the present day in partnership with the Cardiovascular Research Foundation, sponsor of the Sixth International Conference on Cell Therapy for Cardiovascular Disease.

“As we enter the era of studies of phase 3 of more than 300 patients, is vital to the research community to identify appropriate endpoints they correlate with positive clinical results,” said Warren Sherman, MD, director of Regenerative Cardiovascular Research at The Jack H. Skirball Center for Cardiovascular Research. “From there, the design of the essay can optimized to evaluate effective clinical and, hopefully, improve outcomes for patients with CLI.” These patients have a very poor prognosis. “Help with cell therapy would be a huge step forward, and would have implications for the patients with vascular of other organ systems.”

Ed Horwitz, M.D. PhD, CEO of ISCT strongly agreed: “the release of this series of focus groups is the latest initiative whereby ISCT is creating alignment with the academia and industry to accelerate the development and maturation of the field and eventually lead cell therapy treatments to patients faster.” “The intention of ISCT is the international field of regenerative medicine and cell therapy can benefit of groups through public open access to the final report and findings published in peer reviewed journals.”

The initiative of the Group ISCT continues ISCT Industry Community successful launch in August 2010. See: ISCT – media.

ISCT welcomes corporate members to the Industry Community by 2011:

sponsors: Aastrom Biosciences Inc., BD Biosciences Inc. BioLife Solutions Inc., Pfizer Regenerative Medicine Pluristem Therapuetics Inc. partners: CaridianBCT Inc., Sartorius Stedim Biotech GmbH., STEMCELL Technologies Inc. supporters: CellGenix GmbH., B.V. Pharmacell, members: Apceth GmbH & Co. Preservation Solutions Inc, Beike Biotechnology Co.Ltd., JIU Biotech Inc., Tengion Inc., STEMSOFT Software Inc., ZMKS International Cancer Therapy Biotechnology Co. Ltd.

The full list of members can be seen on the page of the Community Industry.

ISCT is a global association that promotes the translation of scientific research to provide innovative cell therapies for patients. Established in 1992, their membership and leadership are formed by world medical experts in technology, professional scientists in biotechnology and Pharmacology and experts in regulation around the world focused on aspects preclinical and translational cell therapy product development.

–
References

(1) Hirsch AT et to the. JAMA. 2001; 286: 1317-1324

(2) Hirsch AT et to the. Circulation. 2006; 113:e463 – 654

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips